CoChat

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

Open access

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.

Abstract

Background: Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. Methods: The metabolomic profiling of gut microbiota was characterized in 11 patients affected by non-small cell lung cancer (NSCLC) treated with nivolumab in second-line treatment with anti-PD-1 nivolumab. The metabolomics analyses were performed by GC–MS/SPME and 1 H-NMR in order to detect volatile and non-volatile metabolites. Metabolomic data were processed by statistical profiling and chemometric analyses. Results: Four out of 11 patients (36%) presented early progression, while the remaining 7 out of 11 (64%) presented disease progression after 12 months. 2-Pentanone (ketone) and tridecane (alkane) were significantly associated with early progression, and on the contrary short chain fatty acids (SCFAs) (i.e., propionate, butyrate), lysine and nicotinic acid were significantly associated with long-term beneficial effects. Conclusions: Our preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy. The metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked “indicators” of early progressor and long responder patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-020-02231-0

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Principal component analysis (PCA) of integrated datasets of 1H-NMR and GC–MS/SPME data at T0. a PC score plot. b Loading plot. The first two components explained 47% of the total variance. In green and red circles are represented EP (early progressors, not responders) and LR (long responders) patients, respectively. a Red, early progressors (EPs); green, long responders (LRs). b 1: 1-butanol; 2: 1-hexanol; 3: 1-pentanol; 4: 2,6-dimethyl 4 heptanone; 5: 2-butanone; 6: 2-heptanone; 7: 2-hexanol; 8: 2-nonanone; 9: 2-octanol; 10: 2-octanone; 11: 2-pentanone; 12: 6-methyl-5-hepten-2-one; 13: benzaldehyde; 14: benzeneacetaldehyde; 15: cis-2,6-dimethyl-2,6-octadiene; 16: dimethyl disulfide; 17: dodecane; 18: indole; 19: methyl isobutyl ketone; 20: p-cresol; 21: tridecane; 22: Bile salt 1; 23: Bile salt 2; 24: U1; 25: 2-hydroxy-3-methylbutyric acid 26: U2; 27: valeric acid; 28: isovaleric acid; 29: leucine; 30: valine; 31: isoleucine; 32: U3; 33: 2-oxoisovaleric acid; 34: ethanol; 35: lactic acid; 36: acetoin; 37: 2-aminoisobutyrate; 38: alanine; 39: butyric acid; 40: lysine 41: acetic acid; 42: N-acetyl-moieties; 43: propionic acid; 44: glutamic acid; 45: succinic acid; 46: U4; 47: methionine; 48: aspartic acid; 49: trimethylamine (TMA); 50: 2-oxoglutarate; 51: malonic acid; 52: U5; 53: choline; 54: taurine; 55: methanol; 56: glycine; 57: b-arabinose; 58: b-galactose; 59: b-xylose; 60: b-glucose; 61: U6; 62: uracil; 63: orotic acid; 64: U7; 65: fumaric acid; 66: tyrosine; 67: phenylalanine; 68: U8; 69: formic acid; 70: nicotinic acid
Fig. 1 Principal component analysis (PCA) of integrated datasets of 1H-NMR and GC–MS/SPME data at T0. a PC score plot. b Loading plot. The first two components explained 47% of the total variance. In green and red circles are represented EP (early progressors, not responders) and LR (long responders) patients, respectively. a Red, early progressors (EPs); green, long responders (LRs). b 1: 1-butanol; 2: 1-hexanol; 3: 1-pentanol; 4: 2,6-dimethyl 4 heptanone; 5: 2-butanone; 6: 2-heptanone; 7: 2-hexanol; 8: 2-nonanone; 9: 2-octanol; 10: 2-octanone; 11: 2-pentanone; 12: 6-methyl-5-hepten-2-one; 13: benzaldehyde; 14: benzeneacetaldehyde; 15: cis-2,6-dimethyl-2,6-octadiene; 16: dimethyl disulfide; 17: dodecane; 18: indole; 19: methyl isobutyl ketone; 20: p-cresol; 21: tridecane; 22: Bile salt 1; 23: Bile salt 2; 24: U1; 25: 2-hydroxy-3-methylbutyric acid 26: U2; 27: valeric acid; 28: isovaleric acid; 29: leucine; 30: valine; 31: isoleucine; 32: U3; 33: 2-oxoisovaleric acid; 34: ethanol; 35: lactic acid; 36: acetoin; 37: 2-aminoisobutyrate; 38: alanine; 39: butyric acid; 40: lysine 41: acetic acid; 42: N-acetyl-moieties; 43: propionic acid; 44: glutamic acid; 45: succinic acid; 46: U4; 47: methionine; 48: aspartic acid; 49: trimethylamine (TMA); 50: 2-oxoglutarate; 51: malonic acid; 52: U5; 53: choline; 54: taurine; 55: methanol; 56: glycine; 57: b-arabinose; 58: b-galactose; 59: b-xylose; 60: b-glucose; 61: U6; 62: uracil; 63: orotic acid; 64: U7; 65: fumaric acid; 66: tyrosine; 67: phenylalanine; 68: U8; 69: formic acid; 70: nicotinic acidCC BY · PubMed Central
Fig. 2 Concentration (µmol/g) of proprionic acid (median LR = 7.14 EP = 2.56), nicotinic acid (median LR = 0.08 EP = 0.04), lysine (median LR = 7.51 EP = 4.13), 2-pentanone (median LR = 0; EP = 53.9) tridecane (median LR = 0; EP = 11.03) and p-cresol (median LR = 582.91; EP = 1721.48)
Fig. 2 Concentration (µmol/g) of proprionic acid (median LR = 7.14 EP = 2.56), nicotinic acid (median LR = 0.08 EP = 0.04), lysine (median LR = 7.51 EP = 4.13), 2-pentanone (median LR = 0; EP = 53.9) tridecane (median LR = 0; EP = 11.03) and p-cresol (median LR = 582.91; EP = 1721.48)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 209

Metadata

Authors
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., Giampaoli, O., Miccheli, A., Zizzari, I. G., Nuti, M., Putignani, L., & Marchetti, P.
Affiliations
  • Policlinico Umberto I (IT)
  • Bambino Gesù Children's Hospital (IT)
  • Sapienza University of Rome (IT)
  • Azienda Ospedaliera Sant'Andrea (IT)
Corresponding author
Putignani, Lorenza
Venue
Journal of Translational Medicine
Published
2020-02-03
Volume
18
Issue
1
Pages
49-49
ISSN
1479-5876 (ISSN-L)
OpenAlex
W3008213618
Cited by
209
References
58
Citations by year
2026: 21 · 2025: 37 · 2024: 37 · 2023: 38 · 2022: 33 · 2021: 32 · 2020: 11
FWCI
9.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
Funders
Ministry of Health (Ricerca Corrente 201802G004314)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
non-small cell lung cancer, immune checkpoint inhibitors, nivolumab, anti-PD-1 therapy, immunotherapy response prediction, short-chain fatty acids, 2-pentanone, tridecane, disease progression, personalized cancer management, microbiome biomarkers
MeSH terms
Gastrointestinal Microbiome, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. https://app.cochat.ai/papers/10.1186/s12967-020-02231-0
The paper
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., Giampaoli, O., Miccheli, A., Zizzari, I. G., Nuti, M., Putignani, L., & Marchetti, P. (2020). Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. Journal of Translational Medicine. https://doi.org/10.1186/s12967-020-02231-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.